Glucose Monitoring (CGM)
•7 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (7)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Continuous glucose monitoring (CGM) devices represent a major product category within Abbott's Diabetes Care portfolio, notably the FreeStyle Libre system.
|
$220.15B |
$124.48
-1.68%
|
|
MDT
Medtronic plc
Diabetes-focused devices (Simplera Sync, insulin-delivery ecosystems) align with Blood Glucose Monitoring (CGM).
|
$119.45B |
$91.75
-1.58%
|
|
DXCM
DexCom, Inc.
DexCom's core product is continuous glucose monitoring (CGM), i.e., glucose monitoring devices sold as CGM systems.
|
$27.15B |
$68.56
-0.96%
|
|
AHCO
AdaptHealth Corp.
Potentially offers glucose monitoring devices/systems to diabetes patients as part of diabetes care.
|
$1.28B |
$9.21
-2.80%
|
|
KNW
Know Labs, Inc.
Core product: KnowU CGM wearable and glucose monitoring device.
|
$16.05M |
$2.14
|
|
OSRH
OSR Holdings, Inc.
Planned acquisition of Woori IO's noninvasive CGM technology anchors OSRH in the Glucose Monitoring (CGM) category.
|
$14.34M |
$0.72
-3.28%
|
|
TRIB
Trinity Biotech plc
Directly manufactures glucose monitoring hardware (CGM) and wearable biosensors with an accompanying data platform.
|
$7.67M |
$1.00
-0.42%
|
Loading industry trends...
Loading research report...
